Skip to main content

Table 2 Plasma cytokines portraits of primary ITP patients (pg/ml)

From: Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment

 

Health control (n = 10)

Primary ITP (n = 23)

Eotaxin-1/CCL11

220.40 (195.40–220.40)

154.5 (106.80–189.10)***

Eotaxin-2 (×103)

1.17 (0.84–2.20)

0.92 (0.49–1.41)

G-CSF

825.40 (562.20–855.90)

76.70 (37.00–175.90)***

GM-CSF

80.05 (66.35–97.28)

11.00 (8.00–16.90)***

I-309

83.70 (68.45–134.50)

33.70 (19.60–55.70)***

ICAM-1 (×103)

39.40 (16.75–43.33)

21.87 (6.46–45.08)

IFNγ (×103)

0.79 (0.71–0.94)

0.16 (0.12–0.20)**

IL-1α (×103)

1.16 (0.94–1.33)

0.20 (0.11–0.45)***

IL-1β

65.75 (59.90–79.70)

37.80 (24.10–47.50)***

IL-1ra (×103)

1.28 (1.01–1.63)

0.35 (0.26–0.41)***

IL-2

264.90 (187.80–343.20)

44.90 (33.10–71.60)***

IL-4

415.40 (340.80–504.10)

110.5 (54.7–164.0)***

IL-5

185.40 (158.00–243.40)

42.10 (32.70–51.60)***

IL-6

83.90 (59.03–101.40)

16.50 (7.90–26.80)***

IL-6R (×103)

17.90 (17.86–18.78)

17.80 (17.80–18.90)

IL-7

130.30 (96.93–147.60)

26.20 (22.10–34.60)***

IL-8

99.40 (75.40–121.80)

11.90 (7.70–19.30)***

IL-10

94.45 (63.40–192.20)

17.10 (11.10–23.40)***

IL-11 (×103)

1.43 (1.07–1.93)

0.41 (0.24–0.53)***

IL-12p40

15.85 (12.20–26.78)

13.50 (4.50–18.10)

IL-12p70

41.85 (28.08–55.05)

7.30 (4.60–9.80)***

IL-13

37.80 (26.48–46.33)

10.10 (6.10–12.90)***

IL-15

57.50 (35.35–71.68)

27.60 (12.20–36.90)*

IL-16

124.40 (75.65–171.50)

62.30 (31.80–106.60)*

IL-17A

29.95 (14.50–41.38)

4.00 (1.80–6.80)***

MCP-1 (×103)

0.30 (0.27–0.35)

0.16 (0.12–0.30)**

M-CSF

20.45 (16.28–28.30)

8.20 (4.20–14.00)**

CXCL9/MIG

52.55 (39.88–67.83)

44.60 (25.80–55.00)

MIP-1α/CCL3

25.10 (20.45–30.30)

17.30 (10.60–24.30)*

MIP-1β

97.05 (88.08–140.40)

85.50 (63.50–155.00)

MIP-1d (×103)

1.31 (0.88–2.95)

1.80 (0.95–2.94)

PDGF-BB (×103)

5.36 (3.87–6.72)

0.70 (0.34–1.82)***

RANTES (×103)

14.62 (13.92–15.71)

8.90 (4.08–14.59)**

TIMP-1 (×103)

8.21 (7.00–10.29)

16.13 (11.99–19.03)***

TIMP-2 (×103)

20.46 (13.93–32.76)

11.92 (7.81–14.82)**

TNFα (×103)

1.06 (0.71–1.80)

0.24 (0.15–0.37)***

TNFβ (×103)

0.90 (0.70–1.65)

0.30 (0.21–0.38)***

TNFRI (×103)

5.21 (4.11–5.93)

7.02 (5.40–13.51)*

TNFRII (×104)

1.80 (1.53–2.01)

2.12 (1.82–3.17)*

  1. Data are presented as median (interquartile range)
  2. CCL11 CeC motif chemokine 11, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte–macrophage colony-stimulating factor, ICAM-1 intercellular adhesion molecule-1, IFNγ interferon-gamma, IL interleukin, MCP-1 monocyte chemoattractant protein-1, M-CSF macrophage colony-stimulating factor, CXCL9 CXC ligand 9, MIP macrophage-inflammatory protein, PDGF-BB platelet-derived growth factor BB, RANTES regulated on activation normal T expressed and secreted chemokines, TIMP tissue inhibitor of metalloproteinases, TNF tumor necrosis factor, TNFR tumor necrosis factor receptor
  3. * p < 0.05; ** p < 0.01; *** p < 0.001, ITP(n = 23) compared with HC(n = 10)